Revvity's transformation into a pure-play life sciences and diagnostics firm has stabilized revenue at low single-digit growth (1.3% in Q2 2026) while generating exceptional cash flow, with FCF margin expanding to 24.8% and OCF/NI at 3.70x. However, operating ...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth stabilized at 1.3% in Q2 2026 with gross margin improving to 57.1%, but operating margin remains below 15% (12.2%) due to SG&A escalation to $278.6M, up from $250.2M a year earlier.
Revvity has a 40-year legacy in prenatal healthcare, pioneering Down syndrome screening and developing NIPT systems that transformed care.
Revvity issued revenue guidance expecting Q4 2025 sales of $772 million and full-year 2025 revenue of $2.86 billion, with mid-single-digit growth.
Revvity announced a collaboration with Eli Lilly to integrate Lilly's TuneLab AI models into the Revvity Signals platform, enhancing AI-driven analytics.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $1.41+16.5% vs $1.21 | $711M+1.1% vs $703M |
Q2 2026 May 5, 2026 | $1.06+3.9% vs $1.02 | $711M+1.0% vs $704M |
Q1 2026 Feb 2, 2026 | $1.70+8.3% vs $1.57 | $772M+0.9% vs $765M |
Q4 2025 Oct 27, 2025 | $1.18+3.5% vs $1.14 | $699M-0.1% vs $699M |
Revvity (NYSE: RVTY - Get Free Report) and Cytek Biosciences (NASDAQ: CTKB - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership. Analyst Recommendations This is a summary of current recommendations
Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript
Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Benchmark RVTY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Revvity, Inc. (RVTY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $142.11 | $15.85B | 68.32 | 3.67% | 8.46% | 3.24% | 0.2% | |
| $420.57 | $31.45B | 39.09 | 6.99% | 3.58% | 1.88% | — | |
| $59.67 | $9.08B | -397.80 | 2.08% | -2.03% | -2.87% | — | |
| $1492.34 | $30.16B | 35.39 | 3.98% | 21.91% | — | — | |
| $378.88 | $10.2B | 13.59 | 0.65% | 8.59% | 3.15% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — |
Revvity, Inc. (RVTY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Revvity, Inc. (RVTY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
May 5, 2026·SEC
May 1, 2026·SEC
Get notified when RVTY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Revvity, Inc. (RVTY) stock FAQ — growth, dividends, profitability & financials explained
Revvity, Inc. (RVTY) reported $2.91B in revenue for fiscal year 2025. This represents a 104% increase from $1.43B in 1996.
Revvity, Inc. (RVTY) grew revenue by 3.7% over the past year. Growth has been modest.
Yes, Revvity, Inc. (RVTY) is profitable, generating $237.6M in net income for fiscal year 2025 (8.5% net margin).
Yes, Revvity, Inc. (RVTY) pays a dividend with a yield of 0.20%. This makes it attractive for income-focused investors.
Revvity, Inc. (RVTY) has a return on equity (ROE) of 3.2%. This is below average, suggesting room for improvement.
Revvity, Inc. (RVTY) generated $559.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
